Authors: Feng Wang Wei Liang Chong Lei Renee Kinden Hanfei Sang Yaning Xie Yi Huang Yan Qu Lize Xiong
Publish Date: 2014/10/30
Volume: 52, Issue: 3, Pages: 1458-1466
Abstract
Hyperbaric oxygen HBO therapy and memantine a noncompetitive NMDA antagonist are both promising treatment strategies for improving stroke prognosis However HBO’s narrow therapeutic time window 6 h poststroke and the adverse effect of highdose MEM administration limits the use of these therapeutic interventions In this study we investigated whether or not MEM could prolong the narrow therapeutic window of HBO treatment Transient focal cerebral ischemia was induced in male Sprague–Dawley rats by middle cerebral artery occlusion MCAO for 120 min MCAO produced neurobehavioral deficits increased infarction volume increased Evans blue EB content and levels of proinflammatory factors as well as depleted glutathione GSH and reduced catalase CAT and superoxide dismutase SOD activity in the ischemic ipsilateral hemisphere The combination of 5 mg/kg MEM treatment 15 min after the onset of ischemic event and HBO therapy 12 h postreperfusion significantly restored neurologic scores EB concentration and IL10 levels as well as significantly decreased infarct volume and increased antioxidant activity These results imply that the combination of MEM and HBO therapy not only prolongs the therapeutic window of HBO treatment but also lowers the dosage requirement of MEM The mechanism underlying the neuroprotective effects of the combined treatment may lie in alleviated blood–brain barrier BBB permeability inhibited inflammatory response and upregulation of the antioxidant enzyme activity
Keywords: